GENT, Belgium & MALVERN, PA & TOKYO, Japan — H.U. Group Holdings Inc. and its subsidiary Fujirebio have announced the launch of the Lumipulse G sTREM2 assay, a chemiluminescent enzyme immunoassay (CLEIA) designed for use on the fully automated LUMIPULSE® G analyzers. Available for Research Use Only (RUO), the assay enables the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and blood, delivering results in just 35 minutes.
sTREM2 is emerging as a critical biomarker for understanding neuroinflammation, particularly its role in Alzheimer’s disease and other neurodegenerative conditions. By providing insights into microglial activity and inflammatory responses, the biomarker allows researchers to explore the dynamics of neuroinflammation or monitor the effects of therapeutic interventions.
The Lumipulse G sTREM2 assay complements Fujirebio’s existing neuro biomarker portfolio—which includes GFAP, NfL, and pTau. Together, these tools deepen understanding of neurological disease mechanisms and reinforce Fujirebio’s role as a leader in neuro biomarker diagnostics.
“By adding sTREM2 to our neuro portfolio, we’re enabling a more comprehensive view of neurological disease mechanisms,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “sTREM2 complements established biomarkers like GFAP, NfL, and pTau by adding essential insight into neuroinflammation—offering a more complete picture of the disease on a single platform.”
The new assay is fully compatible with LUMIPULSE G analyzers, widely recognized for their reliability and efficiency in clinical research. These automated instruments deliver robust, high-quality results, supporting researchers with a consistent and accessible tool for studying sTREM2 and its broader implications in neurodegeneration research.
This launch underscores Fujirebio’s commitment to advancing biomarker diagnostics and providing innovative solutions that help researchers unlock the complexities of neurological diseases. With sTREM2 now included in its neuro portfolio, Fujirebio is equipping scientists and clinical researchers with powerful tools to drive critical advancements in understanding and treating neuroinflammatory conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.